The Coca-Cola Co K vs Viatris Inc — how do they compare? The Coca-Cola Co K trades at $82.1 (market cap $353.32B), while Viatris Inc trades at $17.37 (market cap $19.79B). The key difference: The Coca-Cola Co K is far larger — about 17.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| KO | VTRS | |
|---|---|---|
Market Cap | $353.32B | $19.79B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $17.39 |
52-Week Low | $65.67 | $8.74 |
Enterprise Value | $383.39B | $32.00B |
Dividend Yield | 2.58% | 2.83% |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $82.05, up 0.6% with a bearish technical signal but strong fundamentals including 27.8% net margin and consistent earnings beats. Recent quarterly EPS exceeded expectations, while analyst consensus is bullish with a $90.67 price target. The company maintains robust cash flow and a 64-year dividend growth streak, supported by stable demand trends noted by Bank of America on April 10, 2026.
Outlook remains positive due to valuation upside and dividend reliability, though technical resistance near $83 and high debt levels pose risks. Investors benefit from defensive positioning amid market volatility, but must monitor regional demand fluctuations and interest rate impacts on borrowing costs.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Trailing returns across standard periods
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →